Neutrophil-to-Lymphocyte Ratio Is a Major Prognostic Factor in Non-small Cell Lung Carcinoma Patients Undergoing First Line Immunotherapy With PembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, Riccardo Ronga et al.|Cancer Diagnosis & Prognosis|2022Cited by 28
Point-of-Care testing: an ally for precision oncologySima Singh, Stefano Cinti, Michelino De Laurentiis et al.|Annals of Research in Oncology|2025Cited by 3
13P High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumabFrancesco Jacopo Romano, Ferdinando Riccardi, Carmela Barbato et al.|Annals of Oncology|2021Cited by 0